A study from VCU Massey Comprehensive Cancer Center published on Jul. 16 found that cancer survivors and their healthcare providers differ in awareness of the risks associated with medical cannabis and their comfort discussing its use. The research surveyed 395 cancer survivors and 62 cancer care providers to understand perspectives on medical cannabis, which is now legal in 47 states, Washington, D.C., and three U.S. territories.
The study reported that while both groups agreed on many aspects of medical cannabis, there were notable differences. Providers were significantly more likely than survivors to report awareness of potential risks related to cannabis use (25% vs. 8.4%). In contrast, 68.5% of survivors said they felt comfortable discussing cannabis with their care team, compared to only 46.7% of providers who felt comfortable bringing up the topic with patients.
Kim, whose research focuses on cancer survivorship and pain management, said, "People are seeking different approaches to avoid or reduce long-term opioid use, and cannabis is one of them." Kim also said, "I see a similar pattern with opioids. Cancer survivors who were already using opioids before diagnosis are more likely to develop dependency or opioid-related problems... I think something similar might apply to cannabis. People who were already using it recreationally before their cancer diagnosis may be more inclined to develop dependency or chronic cannabis use problems, so I think that group may need more careful attention." Kim added, "There should be stronger clinical evidence that clearly shows the benefits outweigh the potential risks. Standardized clinical guidelines regarding cannabis use for cancer survivors would also be helpful, and more education and training on this topic would give providers more confidence in discussing and recommending medical cannabis when appropriate."
Among those surveyed, over half (57.9%) of the survivors who used cannabis had started before their cancer diagnosis; others began after being diagnosed with cancer specifically for symptom management such as pain, nausea or anxiety.
Kim emphasized the need for further research by saying, "We need longitudinal studies establishing causality with biomarkers and objective measures... The data shouldn't just be self-reported outcomes." Ultimately Kim concluded, "Patient-provider communication is really critical. Having open discussions with providers will help reach informed decisions."
